IMVT Immunovant, Inc.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Gravesí ophthalmopathy (GO). We submitted an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in November 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases.

$8.80  +0.31 (3.65%)
As of 09/17/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/19/2019
Outstanding shares:  114,998,871
Average volume:  710,417
Market cap:   $976,340,415
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45258J102
ISIN:        US45258J1025
Sedol:      BJRFSB7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy